Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Grand Brilliance Group Holdings's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.19%.
Grand Brilliance Group Holdings (HKSE:08372) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
Grand Brilliance Group Holdings ROCE % Related Terms
Grand Brilliance Group Holdings ROCE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Brilliance Group Holdings (HKSE:08372) has a ROCE % of 7.19% as of Mar. 2026.
Is Grand Brilliance Group Holdings' ROCE % too high?
Grand Brilliance Group Holdings' current ROCE % is 7.19%. The Medical Distribution industry median ROCE % is 9.03. Grand Brilliance Group Holdings' value of 7.19% is 20.4% below this industry median. Overall, Grand Brilliance Group Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Grand Brilliance Group Holdings' ROCE % compare to MCK and COR?
Grand Brilliance Group Holdings' ROCE % of 7.19% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.03. Grand Brilliance Group Holdings' value of 7.19% is 20.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.03, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Brilliance Group Holdings's current ROCE % of 7.19% is 20.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Brilliance Group Holdings's current ROCE % is 7.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Brilliance Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Grand Brilliance Group Holdings (HKSE:08372) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.12, compared to a current price of HK$0.13 — trading 5.8% above its estimated fair value. The current ROCE % is 7.19% and 20.4% below the Medical Distribution industry median of 9.03. Grand Brilliance Group Holdings' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Grand Brilliance Group Holdings (HKSE:08372), the current ROCE % is 7.19% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Brilliance Group Holdings (HKSE:08372) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Brilliance Group Holdings stock appears to be overvalued.
The current stock price of HK$0.13 is trading 5.8% above its estimated GF Value™ of HK$0.12.
GuruFocus considers Grand Brilliance Group Holdings to be Fairly Valued.
Key valuation signals for HKSE:08372:
ROCE %: 7.19%
GF Value™: HK$0.12 vs. price of HK$0.13 (5.8% above fair value)
Industry Position: 20.4% below the Medical Distribution median
No single metric tells the full story. See the HKSE:08372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Brilliance Group Holdings Ltd is an investment holding. The company is engaged in the business of medical device distribution. The company also provides one-stop medical device solutions, including market trend analysis, sourcing of medical devices, after-sale services, technical support, and training services, medical device leasing services, and quality assurance. Geographically, the company derives revenue from Hong Kong. It serves private hospitals, public hospitals, private clinics, non-profit organizations, universities, and individual end-users in Hong Kong.
66GF Score
Get the complete analysis for HKSE:08372
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08372 has been successfully added to your 
